Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC

Phase 2

Terminated

Brief Summary: The purpose of this study is to investigate the ability of alvimopan to reduce the time to return of bowel function in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Half of the participants will receive alvimopan or and half will receive placebo immediately before and for up to seven days after surgery.

Detailed Description: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a surgical procedure to treat cancer that has spread to the lining of the abdominal cavity (peritoneal metastases). It is associated with a prolonged time for return of bowel function after surgery.

Alvimopan is a drug used to speed up the time for return of bowel function after surgery. It works by blocking the opioid receptors in the gastrointestinal tract, which normally slow down bowel function in patients receiving postoperative opioid pain medication. It has not previously been tested in patients undergoing CRS/HIPEC.

Recruitment & Eligibility

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent.
Scheduled to undergo open (non-minimally invasive) CRS/HIPEC.
Scheduled to receive postoperative pain management with intravenous opioids.
Age > 18 years.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
Women of child-bearing potential with negative pregnancy test prior to initiating study drug dosing.

Exclusion Criteria

Greater than 7 days of consecutive opioid use immediately prior to scheduled surgery.
Child-Pugh Class C hepatic impairment.
End-stage renal disease (GFR < 15 mL/min/1.73 m2 and/or on peritoneal dialysis or hemodialysis).
Complete mechanical bowel obstruction.
Contraindication or inability to tolerate oral medication postoperatively.
Presence of gastrointestinal ostomy after CRS/HIPEC.
Pancreatic or gastric anastomosis performed during CRS/HIPEC.
History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition as alvimopan at the treating investigators discretion.
Severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e. uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness/social situations that would limit compliance with study requirements).
History of myocardial infarction in the 12 months prior to scheduled surgery.
Pregnant or nursing.

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
Alvimopan	Alvimopan	alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge

Primary Outcome Measures

Name	Time	Method
Time to Return of Upper and Lower GI Function	from surgery to discharge (generally no longer than two weeks)	The later of the time from surgery that the participant first tolerates solid food and the time that the participant first passes a bowel movement.

Secondary Outcome Measures

Name	Time	Method
Prolonged Ileus	from surgery to discharge (generally no longer than two weeks)	The proportion of patients who do not pass flatus or bowel movement greater than 7 days from the time of surgery.
Time to Return of Bowel Function Components	from surgery to discharge (generally no longer than two weeks)	The time from surgery until: * The time to first flatus * The time to first bowel movement * The time to tolerance of solid food
Subgroup Analyses	up to 30 days from surgery	All primary and secondary outcomes will be measured in the following subgroups: * 0 vs. 1 or greater bowel anastomoses * 0 vs. 1 or greater visceral resections * high vs. low amount of postoperative opioid use * epidural vs. no epidural
Time to Discharge	from surgery to discharge (generally no longer than two weeks)	The time from surgery until discharge order written.
Serious Adverse Events	up to 30 days from surgery	The number and proportion of serious adverse events.